Quantamental Technologies LLC Purchases 2,880 Shares of Assembly Biosciences Inc (NASDAQ:ASMB)

Quantamental Technologies LLC grew its position in shares of Assembly Biosciences Inc (NASDAQ:ASMB) by 16,941.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 2,897 shares of the biopharmaceutical company’s stock after buying an additional 2,880 shares during the quarter. Quantamental Technologies LLC’s holdings in Assembly Biosciences were worth $39,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently bought and sold shares of ASMB. BNP Paribas Arbitrage SA lifted its position in shares of Assembly Biosciences by 87,340.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 4,367 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Assembly Biosciences by 5.9% during the 1st quarter. Victory Capital Management Inc. now owns 562,399 shares of the biopharmaceutical company’s stock worth $11,074,000 after buying an additional 31,490 shares in the last quarter. Private Advisors LLC lifted its position in shares of Assembly Biosciences by 17.9% during the 1st quarter. Private Advisors LLC now owns 17,724 shares of the biopharmaceutical company’s stock worth $349,000 after buying an additional 2,688 shares in the last quarter. Marshall Wace North America L.P. lifted its position in shares of Assembly Biosciences by 191.5% during the 1st quarter. Marshall Wace North America L.P. now owns 4,431 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 2,911 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Assembly Biosciences by 0.6% during the 1st quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock worth $8,776,000 after buying an additional 2,680 shares in the last quarter. 82.00% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:ASMB remained flat at $$11.35 during mid-day trading on Friday. 143,141 shares of the company were exchanged, compared to its average volume of 152,413. The company has a current ratio of 9.20, a quick ratio of 9.20 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $290.54 million, a price-to-earnings ratio of -2.85 and a beta of 1.44. The company has a 50 day simple moving average of $12.10 and a 200-day simple moving average of $15.36. Assembly Biosciences Inc has a 52 week low of $10.58 and a 52 week high of $38.42.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.41. The company had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $3.90 million. Assembly Biosciences had a negative net margin of 622.25% and a negative return on equity of 46.33%. On average, equities analysts expect that Assembly Biosciences Inc will post -3.79 EPS for the current fiscal year.

ASMB has been the topic of a number of research reports. Chardan Capital reaffirmed a “hold” rating and issued a $30.00 price target on shares of Assembly Biosciences in a report on Wednesday, August 7th. William Blair reaffirmed a “buy” rating on shares of Assembly Biosciences in a report on Tuesday, July 16th. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. ValuEngine raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, BidaskClub cut shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Assembly Biosciences has an average rating of “Hold” and a consensus target price of $33.25.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Article: Different Types of Derivatives

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.